Cancer Cell 2017-07-10

HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL

Christopher J. Ott, Catherine J. Wu

Index: 10.1016/j.ccell.2017.06.008

Full Text: HTML

Abstract

In this issue ofCancer Cell, Qu et al. describe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of response and resistance to histone deacetylase inhibitor therapy. Their “personal regulome” analysis framework reveals chromatin features that may be predictive of clinical response to epigenetic therapy.

Latest Articles:

Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and CHAARTED Studies

2017-07-10

[10.1016/j.ccell.2017.06.007]

MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer

2017-07-10

[10.1016/j.ccell.2017.06.006]

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

2017-07-10

[10.1016/j.ccell.2017.06.005]

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer

2017-07-10

[10.1016/j.ccell.2017.06.004]

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment

2017-07-10

[10.1016/j.ccell.2017.06.003]

More Articles...